The major drawback of current treatment of infectious diseases are challenging due to resistance to antimicrobial agents and their side effects. Benzimidazole and (β-lactam) Azetidinone are the heterocyclic compounds with considerable therapeutic and pharmacological properties. In this view, the series of Azetidinone encompassing Benzimidazole with different substitution were synthesized and evaluated for antibacterial and antitubercular activities. Series of 6 compounds having Benzimidazole and Azetidinone derivatives have been synthesized. These compounds were evaluated for antibacterial and antitubercular activities. In-vitro antibacterial activity of synthesized compound was tested against Gram positive and Gram negative microorganisms (Staphylococcus aureus MTCC 96, Bacillus subtilis MTCC 121 and Escherichia coli MTCC 521) respectively by filter paper disk method and the antitubercular activity against INH resistant Mycobacterium tuberculosis H37Rv, using the L.J. slope method. All the compounds were characterized by UV, IR, Mass and NMR. All Compounds possess a molecular ion M+2 peak due to presence of chlorine. In the 1H NMR δ value obtained in the range of 7.2 to 8.2 signifies the presence of aromatic ring and δ value at about 3.0 to 4.0 corresponds to the presence of methylene protons. In antibacterial screening all compounds found to have more activity against gram negative bacteria E.coli. Compounds 6a, 6d and 6e found to have better antibacterial activity against gram negative bacteria E.coli. Compound 6f have better antibacterial activity against gram+ve bacteria S.aureus and B.subtilis as compared to other synthesized compounds. Among the ring substituted azetidinone derivatives (6a to 6f) were tested for their antitubercular activity in vitro against INH resistant Mycobacterium tuberculosis H37Rv, using the L.J. slope method. Compounds 6a and 6e were found to be most potent among the series having MIC 100 μg/ml, others synthesized compounds were found to be active (having MIC 250μg/ml: 6b, 500μg/ml: 6d & 6f, 750 μg/ml: 6c). None of the compound was found to be equipotent with standard isoniazid.
Loading....